01710nas a2200193   4500000000100000008004100001260001200042653002200054100001100076700001500087700001100102700001200113700001700125700001500142245017000157856012000327520105500447022001401502       2021                            d  c12/202110aalbendazole (ALB)1 aPion S1 aChesnais C1 aWeil G1 aLouya F1 aBoussinesq M1 aMissamou F00aImpact of Semi-Annual Albendazole on Lymphatic Filariasis and Soil-Transmitted Helminth Infection: Parasitological Assessment after 14 Rounds of Community Treatment.  uhttps://www.ajtmh.org/downloadpdf/journals/tpmd/aop/article-10.4269-ajtmh.21-0731/article-10.4269-ajtmh.21-0731.xml3 a<p>Between October 2012 and October 2015, we conducted a community trial to assess the impact of semi-annual (twice yearly) community treatment with albendazole on lymphatic filariasis in Seke Pembe, a village in the Republic of the Congo. Semi-annual community treatment with albendazole has been continued in the community since October 2015. We conducted an additional parasitological assessment survey in October 2019, 6 months after the 14th round of semi-annual treatment. Between October 2012 and October 2015, Wuchereria bancrofti antigenemia and microfilaremia rates in the community had decreased from 17.3% to 4.7% and from 5.3% to 0.3%, respectively. In October 2019, the antigenemia rate had decreased further to 2.8% (19 of 687). No microfilariae were found in night blood smears from persons with circulating filarial antigenemia (0 of 16), suggesting that W. bancrofti transmission has been interrupted in Seke Pembe. Semi-annual albendazole treatments also reduced significantly infection rates with soil-transmitted helminths.</p>
  a1476-1645